MYIDYL Drug Patent Profile

When do Myidyl patents expire, and what generic alternatives are available?

Myidyl is a drug marketed by Usl Pharma and is included in one NDA.

The generic ingredient in MYIDYL is triprolidine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the triprolidine hydrochloride profile page.

Summary for MYIDYL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	50
Patent Applications:	641
DailyMed Link:	MYIDYL at DailyMed

US Patents and Regulatory Information for MYIDYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Usl Pharma	MYIDYL	triprolidine hydrochloride	SYRUP;ORAL	087963-001	Jan 18, 1983		DISCN	No	No

Last updated: July 27, 2026

MYIDYL (methadone hydrochloride) Market Dynamics and Financial Trajectory: Revenue Drivers, Pricing Pressure, and Exclusivity Outlook

MYIDYL is the brand for methadone hydrochloride used in opioid use disorder and pain management. Market dynamics are shaped by (1) Medicaid and managed-care formulary access, (2) opioid use disorder treatment demand, (3) substitution with generics, and (4) safety-focused prescribing controls. Financial trajectory for the brand depends on the remaining regulatory exclusivity for the specific MYIDYL product presentation, the aggressiveness of generic entry at equivalent dosage forms, and payer contracting.

No complete, product-specific dataset (FDA Orange Book listing for MYIDYL by strength and dosage form, verified NDA/ANDA numbers, current sales, and modeled exclusivity dates) is available in the provided materials, so a complete revenue timeline and precise patent-exclusivity forecast cannot be produced without risking factual errors.

What market dynamics drive MYIDYL sales in the US opioid treatment market?

MYIDYL competes in a heavily genericized methadone segment where formulary placement and contract pricing drive net revenue more than brand marketing. For opioid use disorder and pain, treatment continuity matters because switching from one methadone product to another can create clinical and logistical barriers. That reduces churn at the margin but does not eliminate payer pressure.

Which payer levers determine MYIDYL net pricing?

Key determinants:

• Formulary tier placement (preferred vs non-preferred)
• Prior authorization requirements and step therapy designs
• Medicaid reimbursement controls by state
• Managed care rebate structures
• Wholesale acquisition cost and contract discounting

How does opioid use disorder demand affect MYIDYL volume?

Demand tracks with:

• Patient enrollment in opioid use disorder programs
• Clinic capacity and prescribing patterns
• Trends in illicit opioid exposure and diversion control
• Access to take-home dosing policies (where applicable)

What supply and substitution factors matter most?

In methadone, continuity of supply is operationally critical. Brand share tends to decline when:

• Generics expand coverage broadly
• Multiple generic manufacturers bid aggressively on contracts
• Bioequivalence waivers or product equivalence reduce “brand preference” in payer rules

How has MYIDYL’s financial trajectory typically evolved versus generic methadone?

In methadone, the usual financial pattern is:

• Higher margin at launch and during exclusivity
• Rapid net-sales erosion after generic entries
• Stabilization only when contracting locks in limited brand use or when specific presentation advantages persist

For a brand to keep revenue longer than peer methadone brands, it must maintain:

• Robust payer access (preferred listing)
• Durable patient continuity
• Minimal safety-related disruptions that push prescribers away from the product

A precise MYIDYL revenue curve (annual net sales, gross-to-net bridge, and quarter-by-quarter trends) cannot be stated because no MYIDYL sales series, SEC filings, or payer coverage data are provided.

When does MYIDYL lose exclusivity and face generic competition risk?

Generic competition risk is driven by:

• Regulatory exclusivity tied to the MYIDYL NDA (or supplement) specific to the marketed strength and dosage form
• Patent expiration and any remaining listed exclusivities in the Orange Book
• Conversion from brand exclusivity to generic substitution cycles after approval of eligible ANDAs

A complete exclusivity timetable for “MYIDYL” requires product-specific Orange Book and FDA exclusivity data by NDA number, strength, and dosage form. Without those listings, a correct loss-of-exclusivity date cannot be produced.

What patents protect MYIDYL and how strong is the patent estate?

For small-molecule methadone brands, the patent estate often concentrates in:

• Composition of matter
• Formulation or manufacturing process
• Method of use claims for particular treatment regimens or populations

Strength depends on:

• Claim scope and remaining term
• Whether key claims are listed in the Orange Book for the exact product
• The history of ANDA Paragraph IV challenges (if any)

No patent numbers or assignees tied specifically to MYIDYL are provided in the prompt, so a quantified patent-strength assessment and expiration-by-expiration schedule cannot be constructed without generating inaccuracies.

What is the Orange Book status of MYIDYL (NDA listings, patents, exclusivities)?

Orange Book status is the primary gating input for:

• Listed patents by submission number
• Drug substance exclusivity and drug product exclusivity
• Pediatric exclusivity and orphan exclusivity (if applicable)
• Patent-expiration triggers for generic eligibility

The prompt does not include MYIDYL Orange Book listings (NDA/ANDA identifiers, submission numbers, patent list numbers, or exclusivity codes). A correct Orange Book table cannot be produced.

Which generic competitors and ANDA filings threaten MYIDYL?

Methadone’s competitive landscape is structurally genericized. The most common threat pattern is:

• Multiple ANDAs for equivalent strengths and dosage forms
• Rapid market share shifts after FDA approval and payer contracting changes
• Pharmacy-level substitution that reduces branded dispensing

A precise list of MYIDYL-challenging ANDAs (including Paragraph IV certifications) requires the Orange Book patent list and FDA ANDA approval history for the specific MYIDYL presentation.

What patent litigation or Paragraph IV challenges affect MYIDYL?

Paragraph IV litigation timing can reshape generic entry by:

• Triggering 30-month stay (if triggered by a compliant Notice of Paragraph IV Certification)
• Producing settlement agreements that delay market launch or narrow generic labeling
• Establishing “design-around” pathways via different strengths or formulation choices

No litigation docket data, settlement terms, or Paragraph IV notices for MYIDYL are provided. A litigation timeline would therefore be non-actionable without verified case facts.

How do formulations, strengths, and dosage forms change MYIDYL competitiveness?

For methadone brands, competitiveness can hinge on:

• Availability across common strengths
• Dispensing convenience (where applicable)
• Stability and handling characteristics under clinical workflows
• Labeling differences that affect prescriber adoption

A formulation-by-formulation market risk assessment requires the exact MYIDYL dosage forms and strengths and their corresponding generic equivalents.

How does MYIDYL compare with other methadone brands on pricing and share dynamics?

Comparative analysis in methadone typically shows:

• Brand share erosion post-generic entry
• Net price compression driven by AMP/Medicaid and rebate contracting dynamics
• Differences primarily explained by payer status and patient continuity, not pharmacologic differentiation

A MYIDYL-vs-peer comparison requires brand name set, WAC/AMP history, Medicaid rebate status, and sales by product presentation.

What is the regulatory pathway impact on MYIDYL demand (NDA vs ANDA vs distribution controls)?

Methadone products face:

• Risk evaluation and mitigation requirements (as applicable)
• State-level controls and opioid treatment program compliance
• Controlled substance handling and dispensing workflows

Demand response to regulation is usually indirect:

• Prescribing behavior changes with risk management policies
• Pharmacy access constraints can limit utilization regardless of brand price

A regulatory pathway impact assessment requires knowing whether MYIDYL is an NDA product, which ANDA equivalents exist, and whether any post-market safety labeling changes occurred.

Key Takeaways

• MYIDYL market dynamics are dominated by payer contracting, formulary placement, and the structural genericization of methadone rather than product differentiation.
• Financial trajectory for MYIDYL is expected to follow a typical brand-to-generic erosion curve, with continuity of patient treatment providing limited revenue durability.
• Precise exclusivity timelines, Orange Book status, patent coverage strength, Paragraph IV risk, and litigation timing cannot be stated from the provided prompt without product-specific FDA and patent listings.
• Actionable next steps for an investor, licensor, or litigant require Orange Book-linked analysis by MYIDYL NDA submission, strength, and dosage form, then mapping ANDA competition and any litigation or settlement delays to the launch calendar.

FAQs

1. What makes methadone brands lose market share fastest after generic approvals?
   Payer preferred status shifts, aggressive contract discounting by generics, and pharmacy-level substitution that reduces branded dispensing.

2. How do Medicaid dynamics affect MYIDYL net revenue versus commercial payers?
   Medicaid pricing and reimbursement mechanics typically compress net revenue faster than commercial rebates when generics widen coverage.

3. Do exclusivity types (patent vs pediatric vs marketing exclusivity) change generic entry timing for methadone brands?
   Yes, exclusivity triggers can delay ANDA eligibility windows even when generics are otherwise bioequivalent.

4. How does take-home dosing policy influence methadone product demand?
   It affects clinic workflow, patient stability, and throughput, which can move utilization volume between treatment programs.

5. What data best predicts MYIDYL’s future pricing pressure?
   Coverage footprint in managed care formularies and the number of equivalent ANDA-approved manufacturers with aggressive contract participation.

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US FDA.
2. FDA Drug Approval Reports and ANDA approval history resources. US FDA.